Revvity Inc. (RVTY)

Nov 10, 2026

The global in vitro toxicology testing market, valued at US$14 billion in 2025, is projected to reach US$27.4 billion by 2032, driven by regulatory shifts away from animal testing and advancements in human-relevant models, AI, and high-throughput screening. This growth is significantly influenced by pharmaceutical, biotechnology, cosmetics, and food safety industries adopting these technologies to accelerate safety assessments and reduce development costs. Key players like Thermo Fisher Scientific, Merck, Eurofins, and Bio-Rad are at the forefront of this market disruption.

Nov 6, 2026

Shares of Revvity Inc. (RVTY) rose 2.84% on Friday, outperforming the S&P 500 Index which gained 0.31%, and the Dow Jones Industrial Average which fell 0.46%. This increase ended a two-day losing streak for the stock, with shares closing at $155.11.

Nov 6, 2026

On November 4, Revvity (RVTY) experienced a net outflow of $25.3 million from ETFs, primarily driven by DFSV, which significantly cut its stake. This selling activity followed four consecutive days of net buying for the company's stock. Despite 25 ETFs buying shares compared to 7 selling, the selling amounts were larger, indicating a shift in ETF sentiment for Revvity.

Nov 5, 2026

Several companies experienced significant stock movements on Tuesday following their third-quarter 2026 financial results. Regal Rexnord, Advanced Energy, and Revvity saw their stock prices rise due to strong earnings and raised guidance, while Camping World and Shopify faced declines after missing Wall Street expectations. The article highlights key financial figures and business updates for each company.

Nov 3, 2026

Revvity, Inc. (RVTY) reported strong Q3 2026 results, with adjusted EPS of $1.38 and revenue of $728.9 million, both exceeding analyst expectations. The diagnostics and research company saw significant growth in its Life Sciences segment and raised its full-year EPS guidance. Despite the positive financial performance, the stock traded down 3.4%, indicating market skepticism or profit-taking.

Nov 3, 2026

This article compares Altria (MO) and Philip Morris International (PM) for retirees, highlighting their differing appeals. Altria offers a higher current dividend yield and trades at a steeper discount, making it attractive for immediate income. Philip Morris, however, boasts faster dividend growth, less leverage, and a stronger focus on smoke-free products, positioning it as a better long-term investment for income growth.

Nov 3, 2026

Revvity Inc. (NYSE: RVTY) stock reached a new 52-week high after reporting stronger-than-expected third-quarter results and increasing its full-year earnings forecast. Growth was fueled by robust demand from pharmaceutical and biotech customers, as well as increasing interest in AI-related technologies. The company beat analyst estimates for adjusted earnings per share and revenue, prompting an upward revision of its fiscal 2026 outlook.

Nov 3, 2026

On Tuesday, while the Dow Jones dipped, several major stocks experienced significant gains. Fabrinet, EverQuote, Lattice Semiconductor, and Fiserv were among the companies that saw their shares rise following better-than-expected quarterly financial results and, in some cases, optimistic future guidance. Other notable gainers included Ibotta Inc, Xtend AI Robotics, Aehr Test Systems, and Graphic Packaging Holding Co, all reporting strong financial performance or strategic achievements.

Nov 3, 2026

Shares of Revvity Inc. (RVTY) rose 7.84% to $163.48 on Tuesday, outperforming the S&P 500 Index which gained 0.36%, and the Dow Jones Industrial Average which fell 0.38%. This increase broke a two-day losing streak for the stock.

Nov 3, 2026

Revvity, Inc. (NYSE:RVTY) reported stronger-than-expected third-quarter 2026 earnings and revenue, leading to a nearly 6% jump in shares during premarket trading. The health sciences technology company exceeded analyst forecasts with adjusted earnings per share of $1.37 and revenue of $729 million, driven by strong performance in both its Life Sciences and Diagnostics segments. Consequently, Revvity raised its full-year 2026 earnings and revenue guidance, reflecting confidence in continued business momentum despite the pending divestiture of its China Immunodiagnostics business.

Nov 3, 2026

Amneal Pharmaceuticals reported a 10% increase in third-quarter 2026 revenue, reaching $863 million, despite recording a net loss of $22 million. Adjusted earnings per share rose 53% to $0.26, surpassing analyst expectations, and adjusted EBITDA climbed 30% to $207 million. The company raised its full-year revenue forecast to $3.15 billion–$3.25 billion but reduced its operating cash flow guidance.

Nov 3, 2026

Revvity reported a 4.3% year-over-year increase in third-quarter 2026 revenue to $729 million, with adjusted earnings rising to $1.38 per share. The company's pro forma revenue grew 7% to $710 million, leading to a 5% gain in Revvity shares. Revvity also raised its full-year guidance, projecting $2.86 billion in pro forma revenue and adjusted earnings of $5.40–$5.45 per share.

Nov 3, 2026

Revvity reported strong Q3 2026 financial results with 7% pro forma organic growth, driven by a 9% increase in the life sciences segment and solid performance in diagnostics. The company exceeded adjusted EPS expectations and raised its full-year organic growth and EPS guidance, attributing success to improving market demand, expanding AI-related opportunities across its portfolio, and operational efficiencies. New product launches in software and diagnostics also contributed to the positive outlook.

Nov 3, 2026

Revvity, Inc. (RVTY) reported strong third-quarter results, exceeding Wall Street expectations with adjusted earnings of $1.38 per share on revenue of $709.6 million. The company's profit was $62.3 million, or 56 cents per share. Revvity also provided a positive full-year outlook, anticipating earnings between $5.40 and $5.45 per share and revenue of $2.86 billion.

Nov 3, 2026

Revvity, Inc. (RVTY) reported strong third-quarter results, with profits of $62.3 million and adjusted earnings of $1.38 per share, exceeding analyst expectations. The scientific instruments maker also surpassed revenue forecasts, posting $728.9 million in the period, with adjusted revenue at $709.6 million. The company expects full-year earnings between $5.40 and $5.45 per share, with revenue projected to be $2.86 billion.

Nov 3, 2026

Revvity (NYSE: RVTY) exceeded Wall Street's Q3 2026 revenue and non-GAAP profit expectations, with revenue increasing 10.3% year-on-year to $728.9 million and adjusted EPS reaching $1.37. The life sciences company also slightly raised its full-year revenue and adjusted EPS guidance, leading to a 5% surge in its stock immediately after the results were announced. Despite some historical weakness in revenue and operating margin, the company's recent performance and organic growth trends suggest improving momentum.

Nov 2, 2026

Revvity Inc. (RVTY) shares dropped 3.44% to $151.60 on Monday, marking its second consecutive day of losses. This occurred during a mixed trading session where the Dow Jones Industrial Average rose, but the S&P 500 Index fell. The stock's performance lagged behind its competitors.

Nov 2, 2026

Cognex (CGNX) is scheduled to report its third-quarter 2026 results on November 4, 2026, with expected revenues between $300-$320 million and adjusted earnings of 50-54 cents per share. The company's performance is anticipated to benefit from strong industrial demand, automation adoption, and growth in semiconductor, electronics, packaging, and logistics markets, driven by AI investments. However, its short-cycle business nature, logistics concentration, and seasonality could lead to uneven results.

Oct 29, 2026

Shares of Revvity (RVTY) have experienced a 7-day winning streak, increasing 9.6% and adding $1.6 billion to its market value, closing at a one-year high of $165.33. This performance largely outpaced the S&P 500, which only returned 0.7% over the same period, indicating the run is primarily due to Revvity's specific performance rather than broader market trends. However, the company's fundamentals, including revenue growth below the S&P 500 Health Care median and a high trailing earnings multiple, suggest the current price may be asking a lot of the business.

Oct 28, 2026

Revvity Inc. (RVTY) stock saw a strong performance, rallying 2.14% to $165.33 on Wednesday. This gain contributed to its seventh consecutive day of increases, occurring on a positive trading day for the broader market where both the S&P 500 and Dow Jones Industrial Average also rose.